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Abstract
Background: A polymorphism at codon 129 of the prion protein gene (PRNP) is the only well-
known genetic risk factor for Creutzfeldt-Jakob disease (CJD). However, there is increasing
evidence that other loci outside the PRNP open reading frame might play a role in CJD aetiology as
well.
Methods: We studied tau protein gene (MAPT) haplotypic variations in a population of sporadic
and variant CJD patients. We tested 6 MAPT  haplotype tagging SNPs (htSNPs) in a Dutch
population-based sample of sporadic CJD (sCJD) patients and a cognitively normal control group
of similar age distribution. We genotyped the same polymorphisms in two other sample groups of
sCJD cases from Italy and the UK. In addition, we compared MAPT haplotypes between sCJD and
variant CJD (vCJD) patients.
Results: Single locus and haplotype analyses did not detect any significant difference between sCJD
cases and controls. When we compared MAPT haplotypes between sCJD and variant CJD (vCJD)
patients, we found that two of them were represented differently (H1f: 8% in sCJD versus 2% in
vCJD; H1j:1% in sCJD versus 7% in vCJD). However, these two haplotypes were rare in both
groups of patients, and taking the small sample sizes into account, we cannot exclude that the
differences are due to chance. None of the p-values remained statistically significant after applying
a multiple testing correction.
Conclusion: Our study shows no evidence for an association between MAPT gene variations and
sCJD, and some weak evidence for an association to vCJD.
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Background
Tau protein plays a key role in the pathogenesis of several
neurodegenerative disorders. Neurofibrillary tangles
(NFTs) consisting of accumulation of truncated and
hyperphosphorylated tau are one of the hallmarks of
Alzheimer's disease (AD) [1]. NFTs are also present in
other neurodegenerative diseases, including progressive
supranuclear palsy (PSP), cortico basal degeneration
(CBD), Pick's disease, and argyrophilic grain disease and
Parkinson's disease (PD) [1-4]. In patients with sporadic
CJD, the tau protein is profusely released to the CSF [5].
This process is most likely related to the rapid neuronal
damage. Tau quantification with Enzyme Linked Immu-
nosorbent Assay (ELISA) is a very valuable aid for sCJD
diagnosis [6]. In contrast to sCJD, in vCJD there is an
increase of phosphorylated-tau forms in CSF [7]. The
pathogenic implications of this finding are unknown, but
it suggests that tau phosphorylation may differ between
sCJD and vCJD.
The tau protein is encoded by MAPT gene, located in chro-
mosome 17. Mutations in MAPT have been identified in
frontotemporal dementia (FTD) and pallidopontonigral
degeneration [8-13]. There are two common MAPT
extended haplotypes in Caucasians, H1 and H2. The H1
haplotype has been linked to several sporadic neurode-
generative disorders like PSP [14-16], CBD [17], FTD [18],
Parkinson's [19] and some studies suggest to Alzheimer's
disease [20].
A recent study using data from the HapMap project [21]
identified 6 htSNPs capturing 95% of MAPT genetic vari-
ability in Caucasians [22]. The same group showed that
H1c, one of the H1 subhaplotypes, was linked to late
onset AD [20]. In the present study we examined the asso-
ciation between MAPT  haplotypic variants and risk of
sCJD and vCJD.
Methods
Cases were derived from population-based surveys of CJD
carried out by national CJD registries from 1991 to 2005
in Italy (n = 194 sCJD), the United Kingdom (UK) (n = 48
sCJD and 52 vCJD) and the Netherlands (n = 79 sCJD).
All three countries are part of the European CJD surveil-
lance network EuroCJD [23]. Only patients of Caucasian
origin who fulfilled the WHO diagnostic criteria for defi-
nite or probable CJD were included [24]. Definite CJD
diagnosis was based on neuropathological examination.
Probable cases required an appropriate clinical profile,
supported by characteristic findings on MRI, EEG or CSF
14-3-3-protein detection. Whenever possible, all EEGs
and MRIs were reviewed by a member of the surveillance
system and scored for the presence or absence of typical or
characteristic diagnostic features [25,26]. The CSF 14-3-3
immunoassays were performed using Western-blotting
[27]. Healthy controls (n = 309) were participants of the
Rotterdam Study, which is a population-based study of
7385 subjects aged 55 years or older [28]. Controls are all
cognitively normal and from Caucasian origin. Signed
informed consent to participate in genetic research,
approved by the Medical Ethics Committee of the Eras-
mus Medical Center, was obtained from all controls and
patients relatives.
For all patients and controls, DNA has been extracted
from peripheral leucocytes according to a standard proto-
col. We genotyped five polymorphisms, which had been
previously shown to tag the haplotype diversity of MAPT
in Caucasians (Figure 1) [22]. Additionally, the H1/H2
clade was defined by typing the SNP g.8117G>A [number-
ing according to GenBank accession number
AC091628.2], with the allele G tagging H1, and the allele
A tagging H2 [29]. DNA samples were genotyped with a
TaqMan allelic discrimination assay by using the primers
shown in Table 1.
Hardy-Weinberg equilibrium (HWE) was calculated for
the 6 htSNPs genotypes in the control population using χ2
statistics. We set a significance level of 0.01 in order to
take into account the number of tests performed. We
assessed pairwise linkage disequilibrium (LD) between
the 6 htSNPs using D' and r2 calculated from the expecta-
tion-maximization estimated haplotypes (Figure 2). We
used the program SNPStats [30] for the LD analysis. Single
locus analyses were performed using SPSS software ver-
sion 13. Allelic and genotypic frequencies were compared
using χ2 statistics. Adjusted analyses were performed using
multiple logistic regression analysis. Age, gender and
Scheme of MAPT genomic structure showing the position of the 6 SNPs genotyped Figure 1
Scheme of MAPT genomic structure showing the position of the 6 SNPs genotyped.BMC Medical Genetics 2007, 8:77 http://www.biomedcentral.com/1471-2350/8/77
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PRNP M129V genotype were included in the model as
covariates. We first compared Dutch sCJD cases and con-
trols using the Italian and UK sCJD populations as repli-
cation samples. In a separate analysis we compared UK
sCJD with vCJD. Haplotype analyses were performed
using the program hplus [31]. We performed haplotype
analysis comparing controls versus all sCJD patients and
UK sCJD patients with vCJD patients.
Results
Table 2 shows the basic characteristics of our patients and
controls. All htSNPs were in HWE (p > 0.01). Allele fre-
quencies in our control samples were comparable to pre-
vious published data [20].
In the first analysis we tested whether MAPT genetic vari-
ations were associated with risk of sCJD. None of the
htSNPs genotypes showed a statistically significant associ-
ation with the disease when comparing the Dutch cases to
the matched controls nor when comparing the other non-
Dutch patients. Also the pooled analysis was not signifi-
cant. Adjustment for age, gender and PRNP M129V geno-
type did not alter this conclusion. When we compared in
a separate analysis MAPT  genetic variants between UK
sCJD and vCJD, we also failed to find any statistically sig-
nificant association (Table 3).
The htSNPs genotyped allowed us to define the two major
clades, H1 and H2, which have been described in Cauca-
sians in several previous studies [32]. In order to facilitate
comparisons we have adopted the same terminology for
H1 sub-haplotypes as that used by Pittman et al.[22]. We
did not find any evidence of association between any of
the MAPT haplotypes and sCJD. We specifically did not
find association with the subhaplotype H1c, which has
been previously reported to be related to several neurode-
generative diseases. We also compared MAPT haplotypes
between sCJD and vCJD from the UK. We found that the
frequency of two rare haplotypes, H1f and H1j, were sig-
nificantly different in sCJD (p = 0.04) and vCJD patients
(p = 0.01) (Table 4). However, these two variants were
present in a small proportion of patients, and after adjust-
ing by the number of test performed (14 pairwise haplo-
typic comparisons were made) the results were not
statistically significant (p = 0.56 for H1f) and (p = 0.14 for
H1j). When we compared the frequency of these haplo-
types in vCJD versus the Dutch control population, only
the difference in H1j (3% in controls versus 7% in vCJD)
was of borderline significance (p = 0.06).
Discussion
Our study assesses the relationship between MAPT haplo-
typic variations and CJD for the first time. To the best of
our knowledge, there has only been one published article
studying the role of MAPT  in sCJD aetiology [33].
Sánchez-Valle et al. found no association between a poly-
morphism in exon 1 of MAPT in a group of 29 sCJD cases
and 29 controls. We examined 6 htSNPs, which are part of
an extended MAPT  haplotype, in a Dutch population-
based sample of sCJD patients and a cognitively normal
control group of similar age distribution. Statistical analy-
sis revealed no significant differences between cases and
controls, with all p-values higher than 0.05 before correct-
ing for multiple testing. Haplotype analysis still failed to
Table 1: SNP sequence
SNP Primer sequence
Rs242559 AGAAAGTTCTCCCAGGAAACAAGAG
ATTCCTTAGCTGTTACCAGTCACTG
Rs242557 CGTTTCTTCTTCCTTACAAAGCAGTT
TGTCACGGGACCAGGG
Rs3785883 GCTCAGCGATATTGTCACATGAC
AGTGTCGGCTGGATGGAC
Rs2471738 AGTGGCCTGGTTAGAGACCTT
TCTGTCCTGTACCGCAGC
H1/H2 GCCGTCCGCCTCTGT
CATCGGTCGGGGCCA
Rs7521 CCTGCGTGTCCCATCTACAG
TCTTCAGCTTTGAAAAGGGTTACCCBMC Medical Genetics 2007, 8:77 http://www.biomedcentral.com/1471-2350/8/77
Page 4 of 8
(page number not for citation purposes)
detect any significant difference. We genotyped the same
polymorphisms in two other sample groups of sCJD cases
from Italy and the UK. All three populations of cases
showed similar demographical characteristics. Due to
selection bias in the low number of UK sCJD cases tested
(n = 48), valine carriers were overrepresented in this sub-
group. The frequencies of codon 129 genotypes in UK
sCJD cases are similar to those found in other European
countries. Our data do not show association between
PRNP codon 129 and any of the MAPT SNPs. Therefore
our conclusion of no association between MAPT and sCJD
is not affected by the differences in PRNP genotypic distri-
bution in the sample sets.
In our single locus analysis we did not find any significant
difference between UK sCJD and vCJD patients. We found
Linkage disequilibrium (LD) plot showing pairwise correlation between SNPs Figure 2
Linkage disequilibrium (LD) plot showing pairwise correlation between SNPs.
Table 2: Descriptive statistics
Origin Series n % Females % Definite 
diagnosis
Median age 
(range)
PRNP M129V genotype
MM n (%) MV n (%) VV n (%)
NL sCJD 79 59 52 67 (34–87) 48 (67) 16 (22) 8 (11)
controls 309 56 N/A 71 (55–93) 135 (45) 145 (48) 23 (8)
UK sCJD 48 58 50 67 (49–81) 22 (46) 13 (27) 13 (27)
vCJD 52 31 74 25 (12–62) 52 (100) 0 (0) 0 (0)
Italy sCJD 194 57 73 67 (35–87) 141 (73) 31 (16) 22 (11)BMC Medical Genetics 2007, 8:77 http://www.biomedcentral.com/1471-2350/8/77
Page 5 of 8
(page number not for citation purposes)
Table 3: Single locus analysis of the association between MAPT and Creutzfeldt-Jakob disease
SNP (alleles)
rs242559 (A/c) rs242557 (G/a) rs3785883 (G/
a)
rs2471738 (C/t) H1/H2 (G/a) rs7521 (G/a)
Controls
Major allele 
count 
(frequences)
467 (0.76) 382 (0.63) 501 (0.82) 495 (0.81) 469 (0.77) 330 (0.54)
wt 180 (0.60) 123 (0.40) 205 (0.67) 208 (0.68) 183 (0.60) 91 (0.30)
Genotype 
distribution 
(frequences)
wt-v 107 (0.29) 136 (0.45) 91 0.30) 79 (0.26) 103 (0.34) 148 (0.48)
v-v 19 (0.11) 46 (0.15) 10 (0.03) 18 (0.06) 18 (0.06) 67 (0.22)
NL sCJD
Major allele 
count 
(frequences)
116 (0.73) 95 (0.60) 134 (0.85) 124 (0.78) 115 (0.73) 88 (0.56)
wt 47 (0.60) 29 (0.37) 56 (0.71) 50 (0.64) 47 (0.62) 27 (0.35)
Genotype 
distribution 
(frequences)
wt-v 22 (0.28) 37 (0.48) 22 (0.28) 24 (0.31) 21 (0.28) 34 (0.43)
v-v 9 (0.12) 12 (0.15) 1 (0.01) 4 0.05) 8 (0.10) 17 (0.22)
P-values Allelic 0.6 0.71 0.41 0.65 0.75 0.59
Genotypic 0.19 [0.32] 0.87 [0.70] 0.58 [0.76] 0.68 [0.66] 0.27 [0.45] 0.68 [0.71]
Italy sCJD
Major allele 
count 
(frequences)
297 (0.76) 248 (0.64) 319 (0.82) 301 (0.78) 300 (0.77) 205 (0.53)
wt 111 (0.58) 84 (0.44) 133 (0.70) 122 (0.64) 116 (0.62) 54 (0.28)
Genotype 
distribution 
(frequences)
wt-v 75 (0.39) 80 (0.42) 51 (0.28) 57 (0.30) 68 (0.36) 97 (0.51)
v-v 6 (0.03) 28 (0.14) 5 (0.02) 12 (0.06) 4 (0.02) 40 (0.21)
P-values Allelic 0.76 0.54 0.55 0.37 0.34 0.95
Genotypic 0.25 [0.43] 0.75 [0.73] 0.80 [0.20] 0.60 [0.77] 0.14 [0.54] 0.87 [0.78]
UK sCJD
Major allele 
count 
(frequences)
69 (0.72) 65 (0.68) 82 (0.85) 71 (0.74) 69 (0.72) 59 (0.61)
Genotype 
distribution 
(frequences)
wt 25 (0.52) 22 (0.46) 36 (0.75) 28 (0.58) 25 (0.52) 20 (0.42)
wt-v 19 (0.40) 21 0.44) 10 (0.21) 15 (0.31) 19 (0.40) 19 (0.39)
v-v 4 (0.08) 5 (0.10) 2 (0.04) 5 (0.11) 4 (0.08) 9 (0.19)
P-values Allelic 0.37 0.36 0.47 0.13 0.3 0.19
Genotypic 0.65 [0.42] 0.63 [0.47] 0.44 [0.17] 0.31 [0.62] 0.54 [0.31] 0.25 [0.15]
Overall sCJD
Major allele 
count 
(frequences)
482 (0.76) 408 (0.64) 535 (0.84) 496 (0.78) 484 (0.78) 352 (0.56)
wt 183 (0.58) 135 (0.43) 225 (0.71) 200 (0.63) 188 (0.60) 101 (0.32)
Genotype 
distribution 
(frequences)
wt-v 116 (0.36) 138 (0.43) 85 (0.27) 96 (0.30) 108 (0.35) 150 (0.47)
v-v 19 (0.06) 45 (0.14) 8 (0.02) 21 (0.07) 16 (0.05) 66 (0.21)
P-values Allelic 0.84 0.6 0.29 0.2 0.89 0.61
Genotypic 0.92 [0.73] 0.85 [0.66] 0.57 [0.36] 0.46 [0.58] 0.90 [0.87] 0.84 [0.77]BMC Medical Genetics 2007, 8:77 http://www.biomedcentral.com/1471-2350/8/77
Page 6 of 8
(page number not for citation purposes)
some MAPT haplotype frequencies unequally distributed,
but none of the differences remained statistically signifi-
cant after applying a multiple testing correction.
One possible caveat of our study is the fact that we
included a proportion of clinically diagnosed cases (26%
vCJD and 36% sCJD). However, it has been shown that
"probable" cases fulfilling the clinical diagnostic criteria
have a very high positive predictive value (98.5%) [34].
Lack of statistical power could be another explanation for
our results. We think that this is unlikely. As a proof of
principle, the association of sCJD with PRNP M129V gen-
otypes in the overall sample yielded a very low p-value
(<10-11). The sCJD risk of PRNP 129 M homozygotes ver-
sus PRNP 129 heterozygotes was 3.8 folds higher (95%CI
from 2.6 to 5.5). Without multiple testing corrections we
estimated that the statistical power of our genotypic anal-
ysis would be of 85% to detect an odds ratio as low as 1.6.
In order to increase the power of the study, we pooled all
sCJD cases. Therefore, although they were all Caucasians,
in the second stage of the analysis not all sCJD cases and
controls came from the same country. Another caveat of
the study is the fact that the comparison between UK spo-
radic versus variant CJD was not age-matched. However,
to the best of our knowledge, there are not MAPT age-
related variations and, therefore, this should not be a
major issue for our analysis.
UK vCJD
Major allele 
count 
(frequences)
67 (0.66) 64 (0.63) 90 (0.87) 80 (0.78) 67 (0.67) 61 (0.60)
wt 21 (0.41) 19 (0.37) 39 (0.75) 31 (0.61) 23 (0.46) 19 (0.37)
Genotype 
distribution 
(frequences)
wt-v 25 (0.49) 26 (0.51) 12 (0.23) 18 (0.35) 21 (0.42) 23 (0.45)
v-v 5 (0.10) 6 (0.12) 1 (0.02) 2 (0.04) 6 (0.12) 9 (0.18)
P-values Allelic 0.36 0.55 0.84 0.51 0.54 0.88
Genotypic 0.28 [0.26] 0.39 [0.79] 0.99 [0.96] 0.80 [0.60] 0.55 [0.27] 0.65 [0.99]
P-values are not corrected for multiple testing
In brackets p-values adjusted by PRNP M129V genotype, age at onset and gender
wt: wild type
v: variant
sCJD: sporadic Creutzfeldt Jakob disease
vCJD:variant Creutzfeldt Jakob disease
Table 3: Single locus analysis of the association between MAPT and Creutzfeldt-Jakob disease (Continued)
Table 4: Haplotype analysis of the association between MAPT and Creutzfeldt-Jakob disease
Haplot
ype
Alleles Frequency P-value Frequency P-value
rs24255
9
rs24255
7
rs37858
83
rs24717
38
H1/H2 rs7521 Control
s
sCJD UK 
sCJD
UK 
vCJD
H1e A G G C G A 0.25 0.26 ref 0.24 0.2 0.51
H2a C G G C A G 0.23 0.22 0.64 0.28 0.31 ref
H1c A A G T G G 0.12 0.15 0.46 0.16 0.1 0.4
H1d A A G C G A 0.13 0.1 0.08 0.07 0.16 0.18
H1f A G A C G G 0.05 0.05 0.88 0.08 0.02 0.04
H1g A A G C G G 0.05 0.05 0.91 _ _ _
H1h A G A C G A 0.04 0.04 0.64 _ _ _
H1i A A A C G A 0.03 0.03 0.68 _ _ _
H1j A A A T G G 0.03 0.02 0.45 0.01 0.07 0.01
H1b A G G C G G 0.02 0.02 0.55 _ _ _
P-values are not corrected for multiple testing
Included all haplotypes present in both sCJD and vCJD
sCJD: sporadic Creutzfeldt Jakob disease
vCJD:variant Creutzfeldt Jakob diseaseBMC Medical Genetics 2007, 8:77 http://www.biomedcentral.com/1471-2350/8/77
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Conclusion
Our study shows no evidence for an association between
MAPT gene variations and sCJD, and some weak evidence
for an association to vCJD.
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